Published in J Med Case Rep on February 02, 2010
Oxaliplatin-induced severe anaphylactic reactions in metastatic colorectal cancer: case series analysis. World J Gastroenterol (2012) 0.79
Acute oxaliplatin-induced peripheral nerve hyperexcitability. J Clin Oncol (2002) 2.67
The chemotherapeutic oxaliplatin alters voltage-gated Na(+) channel kinetics on rat sensory neurons. Eur J Pharmacol (2000) 1.91
A possible explanation for a neurotoxic effect of the anticancer agent oxaliplatin on neuronal voltage-gated sodium channels. J Neurophysiol (2001) 1.73
Oxaliplatin-related neurotoxicity: interest of calcium-magnesium infusion and no impact on its efficacy. J Clin Oncol (2008) 1.63
Oxaliplatin-associated neuropathy: a review. Ann Pharmacother (2004) 1.62
A review on oxaliplatin-induced peripheral nerve damage. Cancer Treat Rev (2008) 1.55
Acute abnormalities of sensory nerve function associated with oxaliplatin-induced neurotoxicity. J Clin Oncol (2009) 1.37
Oxaliplatin induces hyperexcitability at motor and autonomic neuromuscular junctions through effects on voltage-gated sodium channels. Br J Pharmacol (2005) 1.19
Contribution of presynaptic calcium-activated potassium currents to transmitter release regulation in cultured Xenopus nerve-muscle synapses. Neuroscience (2001) 1.04
The effects of oxaliplatin, an anticancer drug, on potassium channels of the peripheral myelinated nerve fibres of the adult rat. Neurotoxicology (2008) 1.02
Oxaliplatin, an anticancer agent that affects both Na+ and K+ channels in frog peripheral myelinated axons. Gen Physiol Biophys (2006) 0.99
Axonal hyperpolarization associated with acute hypokalemia: multiple excitability measurements as indicators of the membrane potential of human axons. Muscle Nerve (2002) 0.98
A reversible coma after oxaliplatin administration suggests a pathogenetic role of electrolyte imbalance. Eur J Clin Pharmacol (2008) 0.87
Acute bilateral abducens paralysis due to oxaliplatin. J Natl Cancer Inst (2003) 0.80
Hypokalemic weakness in hyperaldosteronism: activity-dependent conduction block. Neurology (2005) 0.79
Patterns of somatic mutation in human cancer genomes. Nature (2007) 38.41
Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes. Nature (2010) 14.50
Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma. Nature (2011) 13.30
Somatic mutations of the histone H3K27 demethylase gene UTX in human cancer. Nat Genet (2009) 10.21
Exome sequencing of gastric adenocarcinoma identifies recurrent somatic mutations in cell adhesion and chromatin remodeling genes. Nat Genet (2012) 4.82
Exome sequencing of liver fluke-associated cholangiocarcinoma. Nat Genet (2012) 3.63
A SUMOylation-defective MITF germline mutation predisposes to melanoma and renal carcinoma. Nature (2011) 3.53
An antioxidant response phenotype shared between hereditary and sporadic type 2 papillary renal cell carcinoma. Cancer Cell (2011) 2.78
Interleukin-8 mediates resistance to antiangiogenic agent sunitinib in renal cell carcinoma. Cancer Res (2010) 2.61
Molecular classification of patients with unexplained hamartomatous and hyperplastic polyposis. JAMA (2005) 2.59
Identification of molecular subtypes of gastric cancer with different responses to PI3-kinase inhibitors and 5-fluorouracil. Gastroenterology (2013) 2.46
Integrated epigenomics identifies BMP4 as a modulator of cisplatin sensitivity in gastric cancer. Gut (2012) 2.36
Exome sequencing identifies distinct mutational patterns in liver fluke-related and non-infection-related bile duct cancers. Nat Genet (2013) 2.15
Genome-wide mutational signatures of aristolochic acid and its application as a screening tool. Sci Transl Med (2013) 2.07
Preparing the "soil": the primary tumor induces vasculature reorganization in the sentinel lymph node before the arrival of metastatic cancer cells. Cancer Res (2006) 1.94
Sunitinib acts primarily on tumor endothelium rather than tumor cells to inhibit the growth of renal cell carcinoma. Cancer Res (2010) 1.85
Hypoxia promotes ligand-independent EGF receptor signaling via hypoxia-inducible factor-mediated upregulation of caveolin-1. Proc Natl Acad Sci U S A (2012) 1.80
Cystic renal neoplasia following conditional inactivation of apc in mouse renal tubular epithelium. J Biol Chem (2004) 1.77
Inhibition of MAPK kinase signaling pathways suppressed renal cell carcinoma growth and angiogenesis in vivo. Cancer Res (2008) 1.76
HRPT2 gene alterations in ossifying fibroma of the jaws. Oral Oncol (2006) 1.72
MicroRNA profiling of human kidney cancer subtypes. Int J Oncol (2009) 1.68
Detection of DNA copy number changes and oncogenic signaling abnormalities from gene expression data reveals MYC activation in high-grade papillary renal cell carcinoma. Cancer Res (2007) 1.66
Gene expression signatures delineate biological and prognostic subgroups in peripheral T-cell lymphoma. Blood (2014) 1.66
Deficiency of FLCN in mouse kidney led to development of polycystic kidneys and renal neoplasia. PLoS One (2008) 1.64
A molecular classification of papillary renal cell carcinoma. Cancer Res (2005) 1.60
Aryl hydrocarbon receptor-interacting protein gene mutations in familial isolated pituitary adenomas: analysis in 73 families. J Clin Endocrinol Metab (2007) 1.53
Comparison of the UCLA Integrated Staging System and the Leibovich score in survival prediction for patients with nonmetastatic clear cell renal cell carcinoma. Urology (2010) 1.52
Serglycin is a theranostic target in nasopharyngeal carcinoma that promotes metastasis. Cancer Res (2011) 1.49
Dual modulation of MCL-1 and mTOR determines the response to sunitinib. J Clin Invest (2016) 1.47
Tubulocystic carcinoma of the kidney: clinicopathologic and molecular characterization. Am J Surg Pathol (2008) 1.47
Loss of parafibromin immunoreactivity is a distinguishing feature of parathyroid carcinoma. Clin Cancer Res (2004) 1.47
Molecular subclassification of kidney tumors and the discovery of new diagnostic markers. Oncogene (2003) 1.42
Reduced Oct4 expression directs a robust pluripotent state with distinct signaling activity and increased enhancer occupancy by Oct4 and Nanog. Cell Stem Cell (2013) 1.42
Genetic and structural variation in the gastric cancer kinome revealed through targeted deep sequencing. Cancer Res (2010) 1.41
Predicting clinical behaviour of breast phyllodes tumours: a nomogram based on histological criteria and surgical margins. J Clin Pathol (2011) 1.38
Inactivation of BHD in sporadic renal tumors. Cancer Res (2003) 1.36
Methylation subtypes and large-scale epigenetic alterations in gastric cancer. Sci Transl Med (2012) 1.35
Parafibromin, a component of the human PAF complex, regulates growth factors and is required for embryonic development and survival in adult mice. Mol Cell Biol (2008) 1.32
Met protein expression level correlates with survival in patients with late-stage nasopharyngeal carcinoma. Cancer Res (2002) 1.32
Janus kinase 3-activating mutations identified in natural killer/T-cell lymphoma. Cancer Discov (2012) 1.30
As an independent unfavorable prognostic factor, IL-8 promotes metastasis of nasopharyngeal carcinoma through induction of epithelial-mesenchymal transition and activation of AKT signaling. Carcinogenesis (2012) 1.26
Parafibromin inhibits cancer cell growth and causes G1 phase arrest. Biochem Biophys Res Commun (2006) 1.25
Somatic pairing of chromosome 19 in renal oncocytoma is associated with deregulated EGLN2-mediated [corrected] oxygen-sensing response. PLoS Genet (2008) 1.20
Renal medullary carcinoma: molecular, pathological and clinical evidence for treatment with topoisomerase-inhibiting therapy. BJU Int (2009) 1.18
The t(1;3) breakpoint-spanning genes LSAMP and NORE1 are involved in clear cell renal cell carcinomas. Cancer Cell (2003) 1.18
Molecular characterization of human telomerase reverse transcriptase-immortalized human fibroblasts by gene expression profiling: activation of the epiregulin gene. Cancer Res (2003) 1.18
Activation of the PI3K/AKT pathway induces urothelial carcinoma of the renal pelvis: identification in human tumors and confirmation in animal models. Cancer Res (2009) 1.15
Novel FH mutations in families with hereditary leiomyomatosis and renal cell cancer (HLRCC) and patients with isolated type 2 papillary renal cell carcinoma. J Med Genet (2011) 1.14
Glypican 3: a novel marker in testicular germ cell tumors. Am J Surg Pathol (2006) 1.14
Melanoma: differences between Asian and Caucasian patients. Ann Acad Med Singapore (2012) 1.12
Two distinct types of blood vessels in clear cell renal cell carcinoma have contrasting prognostic implications. Clin Cancer Res (2007) 1.10
Lymphoblastoid cell line with B1 cell characteristics established from a chronic lymphocytic leukemia clone by in vitro EBV infection. Oncoimmunology (2012) 1.10
Classification of renal neoplasms based on molecular signatures. J Urol (2006) 1.09
Genomic expression and single-nucleotide polymorphism profiling discriminates chromophobe renal cell carcinoma and oncocytoma. BMC Cancer (2010) 1.08
C-kit expression in renal oncocytomas and chromophobe renal cell carcinomas. Hum Pathol (2005) 1.08
Gene expression profiling of favorable histology Wilms tumors and its correlation with clinical features. Cancer Res (2002) 1.06
Gene expression profiling of renal medullary carcinoma: potential clinical relevance. Cancer (2004) 1.06
Innovations and challenges in renal cancer: summary statement from the Third Cambridge Conference. Cancer (2009) 1.04
Innovations and challenges in renal cancer: consensus statement from the first international conference. Clin Cancer Res (2004) 1.02
Expression of alpha-methylacyl-CoA racemase in papillary renal cell carcinoma. Am J Surg Pathol (2004) 1.00
VX680/MK-0457, a potent and selective Aurora kinase inhibitor, targets both tumor and endothelial cells in clear cell renal cell carcinoma. Am J Transl Res (2010) 0.98
Randomized double-blind trial of combined modality treatment with or without amifostine in unresectable stage III non-small-cell lung cancer. J Clin Oncol (2003) 0.98
Genome-wide screening using array-CGH does not reveal microdeletions/microduplications in children with Kabuki syndrome. Eur J Hum Genet (2005) 0.97
Pericyte coverage of differentiated vessels inside tumor vasculature is an independent unfavorable prognostic factor for patients with clear cell renal cell carcinoma. Cancer (2012) 0.97
Identification of copy number alterations and its association with pathological features in clear cell and papillary RCC. Cancer Lett (2008) 0.96
Combined genetic and transcriptional profiling of acute myeloid leukemia with normal and complex karyotypes. Haematologica (2004) 0.96
Evolving roles of oncology pharmacists in Singapore: a survey on prescribing patterns of antiemetics for chemotherapy induced nausea and vomiting (CINV) at a cancer centre. J Oncol Pharm Pract (2008) 0.96
Prospects for vasculature reorganization in sentinel lymph nodes. Cell Cycle (2007) 0.95
Expression of S-100 protein in renal cell neoplasms. Hum Pathol (2006) 0.95
Over expression of insulin-like growth factor binding protein 3 in clear cell renal cell carcinoma. J Urol (2008) 0.95
Identifying cancer-related genes in nasopharyngeal carcinoma cell lines using DNA and mRNA expression profiling analyses. Int J Oncol (2002) 0.94
Radiosensitization by inhibiting STAT1 in renal cell carcinoma. Int J Radiat Oncol Biol Phys (2009) 0.94
Primary CNS germ cell tumors: current epidemiology and update on treatment. Med Oncol (2013) 0.93
Complexity of tumor vasculature in clear cell renal cell carcinoma. Cancer (2009) 0.91
Involvement of the MEN1 gene locus in familial isolated hyperparathyroidism. Eur J Endocrinol (2002) 0.91
Fanconi's anemia in adulthood: chemoradiation-induced bone marrow failure and a novel FANCA mutation identified by targeted deep sequencing. J Clin Oncol (2011) 0.90
High-depth sequencing of over 750 genes supports linear progression of primary tumors and metastases in most patients with liver-limited metastatic colorectal cancer. Genome Biol (2015) 0.89
p38delta/MAPK13 as a diagnostic marker for cholangiocarcinoma and its involvement in cell motility and invasion. Int J Cancer (2010) 0.89
Gene expression profiling of renal cell carcinoma. Clin Cancer Res (2004) 0.89
Expression of the PTTG1 oncogene is associated with aggressive clear cell renal cell carcinoma. Cancer Res (2012) 0.88
Gene expression profiling of early- and late-relapse nonseminomatous germ cell tumor and primitive neuroectodermal tumor of the testis. Clin Cancer Res (2004) 0.88
The effect of Aurora kinases on cell proliferation, cell cycle regulation and metastasis in renal cell carcinoma. Int J Oncol (2012) 0.88
2011 Young Surgeon's Award Winner: high endothelial venules: a novel prognostic marker in cancer metastasis and the missing link? Ann Acad Med Singapore (2012) 0.86
Effect of sildenafil citrate on an orthotopic prostate cancer growth and metastasis model. J Urol (2003) 0.85
Genetic and clinical characterization of sporadic cystic parathyroid tumours. Clin Endocrinol (Oxf) (2002) 0.84
Overexpression of asparagine synthetase and matrix metalloproteinase 19 confers cisplatin sensitivity in nasopharyngeal carcinoma cells. Mol Cancer Ther (2013) 0.84
An association between transient hypokalemia and severe acute oxaliplatin-related toxicity predominantly in women. Acta Oncol (2010) 0.84
A unique case of spontaneous regression of metastatic papillary renal cell carcinoma: a case report. Cases J (2009) 0.84
Human folliculin delays cell cycle progression through late S and G2/M-phases: effect of phosphorylation and tumor associated mutations. PLoS One (2013) 0.84
Altered expression of members of the IGF-axis in clear cell renal cell carcinoma. Int J Oncol (2005) 0.83
Management of kidney cancer in Asia: resource-stratified guidelines from the Asian Oncology Summit 2012. Lancet Oncol (2012) 0.82
Selective loss of chromosome 11 in pheochromocytomas associated with the VHL syndrome. Oncogene (2002) 0.82
Nasal metastases from renal cell carcinoma are associated with Memorial Sloan-Kettering Cancer Center poor-prognosis classification. Chin J Cancer (2011) 0.81
A clinical decision support tool to predict survival in cancer patients beyond 120 days after palliative chemotherapy. J Palliat Med (2012) 0.81
Renal cell carcinoma deep sequencing: recent developments. Curr Oncol Rep (2012) 0.81
Gene expression profiling in kidney cancer: combining differential expression and chromosomal and pathway analyses. Clin Genitourin Cancer (2006) 0.81
The impact of medication therapy management in older oncology patients. Support Care Cancer (2012) 0.80
Molecular classification of breast phyllodes tumors: validation of the histologic grading scheme and insights into malignant progression. Breast Cancer Res Treat (2010) 0.79
First somatic mutation of E2F1 in a critical DNA binding residue discovered in well-differentiated papillary mesothelioma of the peritoneum. Genome Biol (2011) 0.79